β -Blockers
PreclinicalSmall molecule
β -Blockers is one of 5 small molecule programs targeting STEMI. It is currently in Preclinical.
1
Indications
3
Total Trials
1
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
5 competitors in STEMI
#DrugCompanyPhaseTrials
1Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Repatha
UUniversity of California, Los Angeles
Phase 3
Calciparine
BBaxter Healthcare Corporation
Preclinical
Unfractionated Heparin
GSKPreclinical
β -Blockers
QQilu Hospital of Shandong University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Cardiotoxicity1 trial
Cardioprotection on Chemotherapy-Induced Cardiotoxicity
Recruiting·—·Phase 3·NCT06853951·30 enrolled
Hypertensive1 trial
Benidipine-based Comparison of Angiotensin Receptors, β-blockers, or Thiazide Diuretics in Hypertensive Patients
Completed·—·Phase 4·NCT00135551·3,501 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for β -Blockers. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details